Reuters logo
BRIEF-UCB advances Neupro in China
February 5, 2015 / 6:09 AM / 3 years ago

BRIEF-UCB advances Neupro in China

Feb 5 (Reuters) - UCB SA

* Announced positive top-line results from two phase 3 studies evaluating Neupro in treatment of patients in China

* Based on positive results UCB intends to submit a regulatory application in China in 2015 for Neupro in treatment of early- and advanced-stage Parkinson’s disease

* Results from phase 3 study in patients with early-stage Parkinson’s disease demonstrated that rotigotine transdermal patch significantly improved symptoms when compared to placebo Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below